Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Immutep Limited
Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
November 14, 2024
From
Immutep Limited
Via
GlobeNewswire
Tickers
ASX:IMM
IMMP
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
April 24, 2024
From
Immutep Limited
Via
GlobeNewswire
Tickers
ASX:IMM
IMMP
Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023
October 24, 2023
From
Immutep Limited
Via
GlobeNewswire
Tickers
ASX:IMM
IMMP
Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer
October 23, 2023
From
Immutep Limited
Via
GlobeNewswire
Tickers
ASX:IMM
IMMP
Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
May 17, 2023
From
Immutep Limited
Via
GlobeNewswire
Tickers
ASX:IMM
IMMP
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®
May 01, 2023
From
Immutep Limited
Via
GlobeNewswire
Tickers
ASX:IMM
IMMP
Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer
November 29, 2022
From
Immutep Limited
Via
GlobeNewswire
Tickers
ASX:IMM
IMMP
Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination
November 09, 2022
From
Immutep Limited
Via
GlobeNewswire
Tickers
ASX:IMM
IMMP
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.